Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders

Published:2019-09 Issue: Volume:167 Page:133-148
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Faraoni Isabella,Giansanti Manuela,Voso Maria Teresa,Lo-Coco Francesco,Graziani Grazia

Funder

Italian Association for Cancer Research

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference166 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

2. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML;Cheung;Ann. Hematol.,2019

3. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet;Dohner;Blood,2010

4. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2017

5. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia;Ley;N. Engl. J. Med.,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient;Leukemia & Lymphoma;2024-07-02

2. Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality;Cancers;2022-11-24

3. DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1;Biomolecules;2022-03-08

4. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword;Cancers;2021-12-20

5. Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation;Leukemia & Lymphoma;2021-10-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3